Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy

Berruti, Alfredo; Dogliotti, Luigi; Terrone, Carlo; Cerutti, Stefania; Isaia, Giancarlo; Tarabuzzi, R.; Reimondo, Giuseppe; Mari, M.; Ardissone, P; Luca, Stefano De; Fasolis, Giuseppe; Fontana, Dario; Rossétti, S. Rocca; Angeli, Alberto

doi:10.1097/00005392-200206000-00006

Cited by 77 publications

(104 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sleep disorders were only marginally affected, whereas no effect on anxiety was observed. Since depression, quality of life and, to a lesser extent, self body image perception were reciprocally correlated, an interesting issue is whether the depressive symptoms in our series were associated directly with testosterone deficiency or indirectly as a consequence of fatigue, physical impairment, and changes in body image related to ADT [34,35]. A multivariate logistic regression analysis showed that depression was independently associated with ADT and this suggests a direct effect of treatment.…”

Section: Discussionmentioning

confidence: 59%

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Saini

Berruti

Cracco

et al. 2013

Urologic Oncology: Seminars and Original Investigations

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 59%

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Saini

Berruti

Cracco

et al. 2013

Urologic Oncology: Seminars and Original Investigations

Self Cite

View full text Add to dashboard Cite

“…Recent cross-sectional data have demonstrate that men with prostate carcinoma who receive ADT, on average, have BMD measurements that are 6.5-17.3% lower compared with BMD measurements in eugonadal men who are treated without androgen blockade. 5,6,10,14,18 The duration of ADT affects BMD values significantly. Kiratli et al, for example, reported spinal BMD values of 14% less and hip BMD values of 28% less than the values observed in age-matched control individuals after 10 years of ADT, compared with spinal BMD values of 1.7% less and hip BMD values of 5.2% less than the values observed in age-matched controls after only 2 years of ADT.…”

Section: Bmd Changes In Normal Men and In Men With Prostate Carcinomamentioning

confidence: 99%

Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy

Diamond

Higano

Smith

et al. 2004

Cancer

242

View full text Add to dashboard Cite

BACKGROUNDAndrogen‐deprivation therapy (ADT) is prescribed with increasing frequency for men with prostate carcinoma. There is growing concern about the effects of such therapy on the skeleton. In the current review, the authors addressed the current research, diagnostic methods, and treatment recommendations for bone loss and osteoporosis in men with prostate carcinoma who received ADT.METHODSData were obtained from electronic literature searches (for the years 1986 through 2002) and from abstracts and meeting proceedings. All randomized and nonrandomized clinical trials, retrospective studies, and cross‐sectional studies of osteoporosis in men with prostate carcinoma who received ADT with or without other therapies were reviewed.RESULTSThe findings confirmed that ADT resulted in significant bone loss in men with prostate carcinoma. Bone mineral density (BMD) of the hip, as measured by dual‐energy X‐ray absorptiometry (DXA), is considered the preferred site of assessment in older men. Spinal BMD is equally important, although careful interpretation of spinal DXA values is required, because of coexisting facet joint disease and extravertebral calcification. Osteoporosis is diagnosed when BMD is > 2.5 standard deviations below a reference mean. Men with prostate carcinoma who were treated with ADT had average BMD measurements below those of eugonadal men. Rates of bone loss ranged from 2% to 8% in the lumbar spine and from 1.8% to 6.5% in the femoral neck during the initial 12 months of continuous ADT. Retrospective data indicated an increased risk of fracture in men with prostate carcinoma who were treated with ADT.CONCLUSIONSFor men with prostate carcinoma who are at high risk for osteoporosis and fractures, clinical management should be dictated by the results of radiographic and DXA skeletal assessment. Cancer 2004;100:892–9. © 2004 American Cancer Society.

show abstract

“…GnRH agonist significantly decrease lean body mass and increase fat mass in men with prostate cancer [27,[63][64][65][66]. In two prospective studies of men with nonmetastatic prostate cancer, for example, we demonstrated that GnRH agonists decreased lean body mass by 2.7 to 3.8% and increase fat mass by 9.4 to 11.0% from baseline to 1 year [65,66].…”

Section: Treatment-related Changes In Body Compositionmentioning

confidence: 60%

“…GnRH agonists significantly decrease bone mineral density in men with prostate cancer [23][24][25][26][27][28]. Most studies report 2-3% decrease per year in bone mineral density of the hip and spine during initial therapy.…”

Section: Changes In Bone Mineral Density During Androgen Deprivation mentioning

confidence: 99%

Androgen deprivation therapy for prostate cancer: new concepts and concerns

Smith

2007

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

148

129

View full text Add to dashboard Cite

Purpose of review-The aim of this review is to summarize new concepts and concerns regarding treatment-related osteoporosis, diabetes, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.Recent findings-Gonadotropin-releasing hormone agonists increase bone turnover, decrease bone mineral density, and increase fracture risk. Bisphosphonates, selective and estrogen receptor modulators significantly increase bone mineral density during androgen deprivation therapy. Ongoing randomized controlled trials will assess efficacy of denosumab, toremifene, and zoledronic acid to prevent fractures in this setting. Gonadotropin-releasing hormone agonists also increase fat mass, decrease insulin sensitivity, and increase serum lipoproteins. In contrast to the classical metabolic syndrome, however, the phenotype of men during androgen deprivation therapy is characterized by increased high-density lipoprotein cholesterol and preferential accumulation of subcutaneous fat. Gonadotropin-releasing hormone agonists are associated with greater risk of incident diabetes and cardiovascular disease in men with prostate cancer.Summary-Androgen therapy increases risk of fractures, diabetes mellitus, and cardiovascular disease in men with prostate cancer. Current and planned studies will evaluate strategies to prevent these treatment-related adverse effects.

show abstract

Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy

Cited by 77 publications

References 21 publications

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy

Androgen deprivation therapy for prostate cancer: new concepts and concerns

Contact Info

Product

Resources

About